ADIL Adial Pharmaceuticals Inc

$ADIL Amateurs—what else is there to say? For a year and a half, Carry kept spouting nonsense about Phase 3 for AD04 launching in December 2025, yet he was unable to move the project forward at all. It looks like he just used shareholders' money to fund a long vacation before finally packing his bags and leaving.

$ADIL Does it ever make sense to invest in these shares? Carry has done practically nothing for nearly two years. He essentially took a paid vacation on the shareholders' dime. Once the share price plummeted by another 90%, he even granted shares to himself and his team. He did absolutely nothing to advance the drug’s development. Now he’s packed his bags and finally left—and for all his "hard work," he’s getting a severance package, plus three years of free health insurance coverage. It’s madness.

$ADIL You come in as an investor and entrust your money to the company for the drug AD04—based on Carry’s boast a year and a half ago that they would begin Phase 3 at the end of 2025 (he’s a liar)—only for him to now just tuck the drug away in a drawer right before Phase 3. If he’s truly this incompetent, I don’t understand how he managed to stay in leadership for so long. And, of course, his salary is completely out of proportion to the size of a company that doesn’t even have an approved drug.